News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit
-- Dr. Rodino-Klapac, a National Institutes of Health Fellow , is a pioneer in the advancement of gene therapy to treat human disease, whose discoveries have advanced six gene therapy programs from bench to human clinical development -- -- Served as a principal investigator and co-inventor of the
View HTML
Toggle Summary As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS® (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe
-- Sarepta will seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened -- CAMBRIDGE, Mass. , June 01, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on May 31, 2018 , that were
View HTML
Toggle Summary Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies
-- Sarepta strengthens position as a leader in gene therapy; expands rare disease franchise -- -- The program is designed, if successful, to offer first-ever corrective treatments for five distinct forms of Limb-girdle muscular dystrophy (LGMD) --  -- Sarepta is granted exclusive option to acquire
View HTML
Toggle Summary Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments
-- First quarter 2017 EXONDYS 51 ® (eteplirsen) total net revenues of $64.6 million -- -- Sarepta signs exclusive partnership and buy-out option with Myonexus Therapeutics; pipeline expands from 16 to 21 programs -- -- Company announces date of first R&D day, at which clinical data from gene
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , April 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on April 30, 2018 , that
View HTML
Toggle Summary Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Recent Corporate Developments on May 3, 2018
CAMBRIDGE, Mass. , April 23, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report first quarter 2018 financial results
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , March 30, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on March 30, 2018 , that
View HTML
Toggle Summary Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program
-- The Company will award 10 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass. , March 20, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of
View HTML
Toggle Summary Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53
-- The Company met with the FDA Division of Neurology Products in February to obtain guidance on the regulatory pathway for golodirsen -- -- The Company intends to complete a rolling NDA submission for golodirsen by year-end 2018 -- CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Sarepta
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.